지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2020.12
- 수록면
- 110 - 118 (9page)
이용수
초록· 키워드
오류제보하기
Purpose: Breast cancer patients with a human epidermal growth factor receptor 2 (HER2) enriched subtype are known to have higher rates of brain metastases (BM) than other patients. This study aimed to evaluate treatment options and survival outcomes.
Methods: A total of 115 breast cancer brain metastases (BCBM) patients with nearly complete medical records were retrospectively analyzed. Additionally, 36 patients were HER2 enriched types according to histological subtypes. The BM was found by brain magnetic resonance imaging in patients who had neurologic symptoms or by regular screening. Age, breast tumor size, number of BM, histological subtypes, first treatment of breast cancer, estrogen receptor, and HER2 status, stage, local treatment of BM were analyzed. Median overall survival, 5-year survival were analyzed from the data.
Results: The median survival time after BM was 6 months, the mean survival time was 16.3 months, and the 5-year survival after BM was only 8.0%. Factors that significantly affect the survival of BCBM patients include histological subtype, number of BM, use of lapatinib in multivariate analysis. A total of 19 out of 36 HER2 enriched patients were treated with lapatinib or capecitabine. For the treatment of HER2 enriched patients, additional use of blood-brain barrier (BBB) crossing substances, as well as local treatment for BM, significantly improve the survival rate in the Kaplan-Meier method (P=0.001).
Conclusion: A combination of local treatment modality for BCBM and the use of substances that cross the BBB for the HER2 enriched patient improved the survival rate.
Methods: A total of 115 breast cancer brain metastases (BCBM) patients with nearly complete medical records were retrospectively analyzed. Additionally, 36 patients were HER2 enriched types according to histological subtypes. The BM was found by brain magnetic resonance imaging in patients who had neurologic symptoms or by regular screening. Age, breast tumor size, number of BM, histological subtypes, first treatment of breast cancer, estrogen receptor, and HER2 status, stage, local treatment of BM were analyzed. Median overall survival, 5-year survival were analyzed from the data.
Results: The median survival time after BM was 6 months, the mean survival time was 16.3 months, and the 5-year survival after BM was only 8.0%. Factors that significantly affect the survival of BCBM patients include histological subtype, number of BM, use of lapatinib in multivariate analysis. A total of 19 out of 36 HER2 enriched patients were treated with lapatinib or capecitabine. For the treatment of HER2 enriched patients, additional use of blood-brain barrier (BBB) crossing substances, as well as local treatment for BM, significantly improve the survival rate in the Kaplan-Meier method (P=0.001).
Conclusion: A combination of local treatment modality for BCBM and the use of substances that cross the BBB for the HER2 enriched patient improved the survival rate.
목차
INTRODUCTION
METHODS
RESULTS
DISCUSSION
REFERENCES
참고문헌 (31)
참고문헌 신청
Venur VA / 2016 / Targeted therapies for brain metastases from breast cancer / Int J Mol Sci 17:1543
Tham YL / 2006 / Primary breast cancer phenotypes associated with propensity for central nervous system metastases / Cancer 107:696~704
Pestalozzi BC / 2006 / Identifying breast cancer patients at risk for central nervous system(CNS)metastases in trials of the International Breast Cancer Study Group(IBCSG) / Ann Oncol 17:935~944
Nam BH / 2008 / Breast cancer subtypes and survival in patients with brain metastases / Breast Cancer Res 10:R20
Gabos Z / 2006 / Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer / J Clin Oncol 24:5658~5663
Tham YL / 2006 / Primary breast cancer phenotypes associated with propensity for central nervous system metastases / Cancer 107:696~704
Pestalozzi BC / 2006 / Identifying breast cancer patients at risk for central nervous system(CNS)metastases in trials of the International Breast Cancer Study Group(IBCSG) / Ann Oncol 17:935~944
Nam BH / 2008 / Breast cancer subtypes and survival in patients with brain metastases / Breast Cancer Res 10:R20
Gabos Z / 2006 / Prognostic significance of human epidermal growth factor receptor positivity for the development of brain metastasis after newly diagnosed breast cancer / J Clin Oncol 24:5658~5663
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Arterial Spin Labelling-Based Blood-Brain Barrier Assessment and Its Applications
Investigative Magnetic Resonance Imaging
2022 .12
-
Effective Treatment of Solitary Pituitary Metastasis with Panhypopituitarism in HER2-Positive Breast Cancer by Lapatinib
Cancer Research and Treatment
2016 .01
-
Enhanced susceptibility of blood-brain barrier (BBB) to chronic endogenous stimuli by co-exposed xenobiotics
환경독성보건학회 심포지엄 및 학술대회
2021 .10
-
Radiotherapy for Brain Metastases in Southern Thailand: Workload, Treatment Pattern and Survival
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
The Pattern of Care for Brain Metastasis from Breast Cancer over the Past 10 Years in Korea: A Multicenter Retrospective Study (KROG 16-12)
Cancer Research and Treatment
2022 .10
-
Estimation of Survival Rates in Patients with Lung Cancer in West Azerbaijan, the Northwest of Iran
Asian Pacific journal of cancer prevention : APJCP
2015 .01
-
Chronological Improvement in Survival of Patients with Breast Cancer: A Large-Scale, Single-Center Study
Journal of Breast Cancer
2018 .01
-
Brain metastasis from colorectal cancer : a single center experience
Annals of Surgical Treatment and Research
2018 .01
-
Impairment in brain endothelial cells of blood-brain barrier by phthalates
환경독성보건학회 심포지엄 및 학술대회
2019 .04
-
Brain metastasis in human epidermal growth factor receptor 2-positive breast cancer: from biology to treatment
Radiation oncology journal : ROJ
2016 .01
-
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Cancer Research and Treatment
2016 .01
-
Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients
Journal of Breast Disease
2017 .12
-
Phosphorylated S6 Kinase-1 as Predictive Marker of Lapatinib Efficacy in HER2-positive Metastatic Breast Cancer Patients
대한임상종양학회 학술대회지
2015 .02
-
A Survival Analysis of Gastric or Colorectal Cancer Patients Treated With Surgery: Comparison of Capital and a Non-capital City
예방의학회지
2017 .01
-
Open source board based acoustofluidic transwells for reversible disruption of the blood–brain barrier for therapeutic delivery
생체재료학회지
2023 .03
-
[S3-4] Microglial inflammasome-dependent regulation of blood-brain barrier integrity
한국실험동물학회 학술발표대회 논문집
2024 .07
-
Estimating the Survival of Patients With Lung Cancer: What Is the Best Statistical Model?
예방의학회지
2019 .01
-
Isothiazolinone (IT) biocides increase mitochondrial damage-mediated dysfunction and enhance hypoxic- or glycative-stress in blood-brain barrier
환경독성보건학회 심포지엄 및 학술대회
2021 .05
-
Effect of time interval between capecitabine intake and radiotherapy on local recurrence-free survival in preoperative chemoradiation for locally advanced rectal cancer
Radiation oncology journal : ROJ
2017 .01
-
Survival Analysis and Prognostic Factors for Colorectal Cancer Patients in Malaysia
Asian Pacific journal of cancer prevention : APJCP
2016 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0